



## Media Release

10 April 2013

---

### PHARMAXIS ANNOUNCES BRONCHITOL DISTRIBUTOR FOR BRAZIL

---

Pharmaceutical company Pharmaxis (ASX:PXS) is pleased to announce that it has appointed United Medical Ltda as exclusive distributor and sales representative for Bronchitol® in Brazil.

Under the terms of the agreement United Medical has responsibility for sales and marketing, pricing, warehousing, distribution and patient support. United will shortly file a marketing approval application with the Brazilian regulatory agency (ANVISA) based on Bronchitol's Australian approval, a process which is expected to take up to 18 months. Pharmaxis will receive milestone payments ahead of Bronchitol's approval in Brazil.

United Medical is a well-established healthcare company based in São Paulo. It partners with leading global pharmaceutical companies and its sales team has worked closely with the cystic fibrosis medical community in Brazil since 1999.

Pharmaxis CEO Mr Gary Phillips said, "This is an important step forward in our plans to commercialise Bronchitol wherever there are significant markets. Brazil has an estimated 3,500 cystic fibrosis patients with 32 specialist treatment centres and a well funded reimbursement scheme providing access to new medications. It is pleasing to have secured the support of an organisation with United Medical's experience and track record. Pharmaxis has aligned with a distributor early in the process ensuring we are well resourced to bring Bronchitol to cystic fibrosis patients in Brazil."

United Medical has a suite of products associated with the cystic fibrosis market including an inhaled antibiotic, specific pancreatic enzymes and vitamins.

United Medical CEO Mr Roberto L Guttmann said "We believe Bronchitol is an important tool for physicians, being at the same time a simple innovative and well rounded solution to achieve a better quality of life for cystic fibrosis patients. It is an honor for United Medical to make it available here. The Bronchitol distribution agreement with Pharmaxis allows us to build on our strong relationships with the cystic fibrosis community in Brazil."

Bronchitol® is a precision spray-dried form of mannitol, delivered to the lungs by a specially designed, portable inhaler. The product is approved for marketing for patients aged over six years in Australia and for patients aged 18 years and over throughout the European Union.

#ENDS#

**SOURCE:** Pharmaxis Ltd, Sydney, Australia

**CONTACT:** Felicity Moffatt, phone +61 418 677 701 or email [felicity.moffatt@pharmaxis.com.au](mailto:felicity.moffatt@pharmaxis.com.au)

---

**About Pharmaxis**

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory disorders. Its product Aridol® for the assessment of asthma is sold in key international markets. Its product Bronchitol® for cystic fibrosis is recently launched in Europe and Australia and its development pipeline of products includes, Bronchitol for bronchiectasis, PXS64 for the treatment of lung fibrosis, ASM8 for asthma and PXS4728 for fibrotic disease. Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company's head office and manufacturing facilities are located in Sydney. For more information about Pharmaxis, go to [www.pharmaxis.com.au](http://www.pharmaxis.com.au) or contact Investor Relations on phone +61 2 9454 7200.

**About United Medical**

Founded 25 years ago, United Medical represents, with exclusivity in Brazil, a range of innovative and high technology products licensed by Global R&D leader laboratories. These products are vital for patients with severe diseases such cystic fibrosis, HIV and HBV infection, cancer and systemic fungal infection. Working with experts in cystic fibrosis since 1999, United Medical offers a complementary line of products that includes an inhaled antibiotic, specific pancreatic enzymes and vitamins.

**About Bronchitol**

Bronchitol has been developed to help clear mucus (a major source of lung infections), improve lung function and reduce exacerbations in patients with cystic fibrosis. Bronchitol is a proprietary formulation of mannitol administered as a dry powder in a convenient hand-held inhaler. Inhaled mannitol hydrates the lungs, helps restore normal lung clearance, and allows patients to clear mucus more effectively.

**About Cystic Fibrosis**

In a healthy person, there is a constant flow of mucus over the surfaces of the air passages in the lungs, removing debris and bacteria. In CF, an inherited disease, a defective gene disrupts ion transport across the epithelial membrane within cells. In the lungs, this leads to a depletion of the airway surface liquid that normally bathes the cilia, and a resultant reduction in mucociliary clearance. The result is thick, sticky mucus that clogs the lungs, severely restricting the natural airway-clearing process. It also increases the potential for bacteria to become trapped and for inflammation, thus creating an unhealthy lung environment that leads to life-threatening lung infections.

**Forward-Looking Statements**

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive regulatory approval or that we will seek any such approval.

---